Genodermatoses with malignant potential

Current Opinion in Pediatrics

Volumn 19, Issue 4, 2007, Pages 446-454

  Holman, Jennifer D ^a   Dyer, Jonathan A ^a  

^a University of Missouri   (United States)

Author keywords

Genodermatoses; Hereditary cancer syndromes; Malignancy

Indexed keywords

ATM PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANGIOMYOLIPOMA; ATAXIA TELANGIECTASIA; BASAL CELL NEVUS SYNDROME; BLOOM SYNDROME; CANCER DIAGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CARNEY COMPLEX; COLONOSCOPY; CONGENITAL TUMOR; COWDEN SYNDROME; DIGITAL IMAGING; DISEASE ASSOCIATION; DYSKERATOSIS; DYSKERATOSIS CONGENITA; EARLY DIAGNOSIS; EARLY INTERVENTION; ESOPHAGOGASTRODUODENOSCOPY; GARDNER SYNDROME; GASTROINTESTINAL POLYPOSIS; GENE MUTATION; GENODERMATOSIS; HUMAN; INTERVENTION STUDY; KIDNEY CARCINOMA; LEIOMYOMATOSIS; MOLECULAR RECOGNITION; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PEUTZ JEGHERS SYNDROME; PHOTOSENSITIVITY DISORDER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; ROTHMUND THOMSON SYNDROME; SIGMOIDOSCOPY; TUBEROUS SCLEROSIS;

ATAXIA TELANGIECTASIA; BASAL CELL NEVUS SYNDROME; BLOOM SYNDROME; CARCINOMA, RENAL CELL; CELL TRANSFORMATION, NEOPLASTIC; DYSKERATOSIS CONGENITA; HUMANS; KIDNEY NEOPLASMS; LEIOMYOMATOSIS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSES; PEUTZ-JEGHERS SYNDROME; PRECANCEROUS CONDITIONS; ROTHMUND-THOMSON SYNDROME; SKIN DISEASES; TUBEROUS SCLEROSIS; XERODERMA PIGMENTOSUM;

EID: 34447509745     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3282495939     Document Type: Review

References (65)

1. Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genetics 1993; 30:460-464.
2. Gorlin RJ. Nevoid basal cell carcinoma syndrome. Medicine 1987; 66:98-113.
3. Cowan R, Hoban P, Kelsey A, et al. The gene for the naevoid basal cell carcinoma syndrome acts as a tumor-suppressor gene in medulloblastoma. Br J Cancer 1997; 76:141-145.
4. Wilson LC, Ajayi-Obe E, Bernhard B. Patched mutations and hairy skin patches: a new sign in Gorlin syndrome. Am J Med Genet A 2006; 140:2625-2630.
5. Soufir N, Gerard B, Portela M, et al. PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. Br J Cancer 2006; 95:548-553.
6. Evans DG, Farndon PA. Nevoid basal cell carcinoma syndrome. GeneReviews 2002; 20 June.
7. Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet 1994; 50:282-290.
8. Gardner EJ, Richards RC. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet 1953; 5:139-147.
9. Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993; 329:1982-1987.
10. Church H, Simmang C, Standards Task Force, American Society of Colon and Rectal Surgeons, Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of the American Society of Colon and Rectal Surgeons. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 2003; 46:1001-1012.
11. Darling TN, Skarulis MC, Steinberg SM, et al. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 1997; 133:853-857.
12. Xia CY, Darling TN. Rapidly growing collagenomas in multiple endocrine neoplasia type I. J Am Acad Dermatol 2007; 56:877-880.
13. Lakhani VT, You N, Wells SA. The multiple endocrine neoplasia syndromes. Annu Rev Med 2007; 58:253-265. An excellent review of all subtypes of MEN with emphasis on current guidelines for screening and treatment.
14. Fryns JP, Chrzanowska K. Mucosal neuroma syndrome (MEN type IIb). J Med Genet 1988; 25:703-706.
15. Van Zyl JA, Muller GS, Rossouw DJ, Van Velden DJ. Multiple endocrine neoplasia type IIb: a clinicopathological report. J Surg Oncol 1990; 45:282-288.
16. Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Intern Med 2003; 253:616-626.
17. Lips CJ, Landsvater RM, Hoppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994; 331:828-835.
18. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005; 353:1105-1113.
19. Boikos SA, Stratakis CA. Carney complex: the first 20 years. Curr Opin Oncol 2007; 19:24-29. A detailed review of CNC, its history and current status, as well as results of current research.
20. Carney JA. Carney complex: the complex of myxomas, spotty pigmentation, endocrine overactivity, and schwannomas. Semin Dematol 1995; 14:90-98.
21. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86:4041-4046.
22. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003; 22:183-198.
23. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004; 41:323-326.
24. Schaeffer JS, Kamino H, Witkiewicz A, et al. Mucocutaneous neuromas: an underrecognized manifestation of PTEN Hamartoma-tumor syndrome. Arch Dermatol 2006; 142:625-632.
25. Alam NA, Barclay E, Rowan AJ, et al. Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. Arch Dermatol 2005; 141:199-206.
26. Guttmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51-57.
27. Mulvihill JI, Parry DM, Sherman JL, et al. NIH Conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis) an update. Ann Intern Med 1990; 113:39-52.
28. Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006; 5:233-238.
29. Theos A, Korf BR. Pathophysiology of neurofibromatosis type 1. Ann Intern Med 2006; 14:842-849. An excellent overview of NF1 and our current understanding of this disorder.
30. Barkan B, Starinsky S, Friedman E, et al. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res 2006; 12:5533-5542.
31. McCaughan JA, Holloway SM, Davidson R, et al. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of neurofibromatosis type1 patients. J Med Genet 2007; 27 February [Epub ahead of print].
32. Hagel C, Zils U, Peiper M, et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol 2007; 82:187-192.
33. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107:1065-1074. Updated estimates of incidence of MPNSTs.
34. Listernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007; 61:189-198. An important work reviewing one of the great controversial areas in neurofibromatosis - the management and treatment of optic gliomas.
35. Sharif S, Femer R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006; 24:2570-2575.
36. Sharif S, Moran A, Huson S, et al. Women with neurofibromatosis 1 (NF1) are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007; 16 March [Epub ahead of print].
37. Hope DG, Mulvihill JJ. Malignancy in neurofibromatosis. Adv Neurol 1981; 29:33-56.
38. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 (NF1). J Med Genet 2007; 44:81-88.
39. Lucci-Cordesco E, Zito I, Gensini F, Genuardi M. Hereditary nonpolyposis colorectal cancer and related conditions. Am J Med Genet 2003; 122A:325-334.
40. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J Child Neurol 2004; 19:643-649.
41. Gomez MR. Tuberous sclerosis. 2nd ed. New York: Raven Press; 1988.
42. Ewalt DH, Sheffield E, Sparagana SP, et al. Renal lesions growth in children with tuberous sclerosis. Ann N Y Acad Sci 1998; 615:26-35.
43. Verhaaren HA, Vanakker O, De Wolf D, et al. Left ventricular outflow obstruction in rhabdomyosarcoma of infancy: meta-analysis of the literature. J Pediatr 2003; 143:258-353.
44. Perzkin KH, Bridge MF. Adenomatous and carcinomatous changes in hamartomatous polyps of the small intestine (Peutz-Jeghers syndrome): report of a case and review of the literature. Cancer 1982; 49:971-983.
45. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006; 355:1345-1356. An exceptional overview of the syndrome.
46. de Leng WW, Westerman AM, Weterman M. Nasal polyposis in Peutz-Jeghers syndrome: a distinct histopathologic and molecular genetic entity. J Clin Pathol 2007; 60:392-396.
47. Giardello FM, Bresinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:1447-1453.
48. Cohen P, Kulin H, Ballantine T, et al. An aromatase producing sex-cord tumor resulting in prepubertal gynecomastia. N Engl J Med 1991; 324:317-322.
49. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006; 12:3209-3215. Summary of cancer incidence in a group of patients followed over a reasonable period of time.
50. Mezoff A, Prued'Homme D, Hodges C. Capsule endoscopy in pediatric patients with hamartomatous polyp syndromes. J Pediatr Gastroenterol Nutr 2006; 42:240-242.
51. Brown G, Fraser C, Schofield G. Video capsule endoscopy in Peutz-Jeghers syndrome: a blinded comparison with barium follow-through for detection of small-bowel polyps. Endoscopy 2006; 38:385-390.
52. Udd L, Katajisto P, Rossi DJ, et al. Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. Gastroenterology 2004; 127:1030-1037.
53. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxibus in a colorectal adenoma chemoprevention trial. N Eng J Med 2005; 352:1092-1102.
54. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Eng J Med 2005; 352:1071-1080.
55. Kraemer KH, Patronas NJ, Schiffmann R. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience 2007; 145:1388-1396.
56. Cleaver JE. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 2005; 5:564-573.
57. Magnaldo T, Sarasin A. Xeroderma pigmentosum: from symptoms and genetics to gene-based skin therapy. Cells Tissues Organs 2004; 177:189-198.
58. Yarosh D, Klein J, O'Connor A, et al. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 2001; 357:926-929.
59. German J, Ellis N. Bloom syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease, 8th ed. NY: McGraw-Hill, Inc.; 2001. pp. 733-752.
60. van Brabant AJ, Stan R, Ellis NA. DNA helicases, genomic instability, and human genetic disease. Annu Rev Genomics Hum Genet 2000; 1:409-459.
61. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair 2004; 3:1187-1196.
62. Thorstenson YR, Roxas A, Kroiss R, et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 2003; 63:3325-3333.
63. Reliene R, Schiestl RH. Antioxidants suppress lymphoma and increase longevity in Atm-deficient mice 1-3. J Nutr 2007; 137:229S-232S.
64. Vulliamy TJ, Marrone A, Knight S, et al. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006; 107:2680-2685.
65. Vulliamy T, Dokal I. Dyskeratosis congenita. Semin Hematol 2006; 43:157-166. An excellent review of the current 'picture' of dyskeratosis congenita.